share_log

藥明康德：截至2024年6 月30日止六個月未經審計中期業績公告

WUXI APPTEC: ANNOUNCEMENT OF THE UNAUDITED INTERIM RESULTSFOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Jul 29 13:11

Summary by Futu AI

药明康德公布截至2024年6月30日止六個月未經審計中期業績，收入達人民幣17,240.9百萬元，同比下降8.6%；毛利為人民幣6,700.9百萬元，同比下降11.3%。母公司持有者之應佔溢利為人民幣4,239.8百萬元，同比減少20.2%。每股盈利基本為人民幣1.46元，攤薄為人民幣1.45元。公司為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，擁有超過6,000家活躍客戶基礎。公司在手訂單人民幣431.0億元，剔除新冠商業化項目同比增長33.2%。公司面臨外部環境的不確定性，預計2024年收入可達到人民幣383–405億元，剔除新冠商業化項目後將保持正增長。
药明康德公布截至2024年6月30日止六個月未經審計中期業績，收入達人民幣17,240.9百萬元，同比下降8.6%；毛利為人民幣6,700.9百萬元，同比下降11.3%。母公司持有者之應佔溢利為人民幣4,239.8百萬元，同比減少20.2%。每股盈利基本為人民幣1.46元，攤薄為人民幣1.45元。公司為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，擁有超過6,000家活躍客戶基礎。公司在手訂單人民幣431.0億元，剔除新冠商業化項目同比增長33.2%。公司面臨外部環境的不確定性，預計2024年收入可達到人民幣383–405億元，剔除新冠商業化項目後將保持正增長。
China's WuXi AppTec has released unaudited H1 2024 results, with revenue of RMB 1.72409 billion, down 8.6% YoY, and gross profit of RMB 0.67 billion, down 11.3% YoY. Net profit attributable to the parent company was RMB 0.42398 billion, a decrease of 20.2% YoY. Basic earnings per share were RMB 1.46, and diluted earnings per share were RMB 1.45. The company provides end-to-end new drug R&D and production services to the global pharmaceutical and life sciences industry and has more than 6,000 active customers. The company has an order backlog of RMB 43.1 billion, a YoY increase of 33.2% excluding COVID-19 commercialization projects. The company faces external uncertainties, and it is expected that revenue will reach RMB 38.3-40.5 billion in 2024 and will maintain positive growth after excluding COVID-19 commercialization projects.
China's WuXi AppTec has released unaudited H1 2024 results, with revenue of RMB 1.72409 billion, down 8.6% YoY, and gross profit of RMB 0.67 billion, down 11.3% YoY. Net profit attributable to the parent company was RMB 0.42398 billion, a decrease of 20.2% YoY. Basic earnings per share were RMB 1.46, and diluted earnings per share were RMB 1.45. The company provides end-to-end new drug R&D and production services to the global pharmaceutical and life sciences industry and has more than 6,000 active customers. The company has an order backlog of RMB 43.1 billion, a YoY increase of 33.2% excluding COVID-19 commercialization projects. The company faces external uncertainties, and it is expected that revenue will reach RMB 38.3-40.5 billion in 2024 and will maintain positive growth after excluding COVID-19 commercialization projects.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated